03.18.09
Vetter Pharma-Fertigung GmbH & Co. KG (VPF) will launch a new subsidiary, Vetter Pharma International GmbH (VPI), on April 1, 2009. VPI will be responsible for all Vetter sales, marketing and customer service activities on a worldwide level.
Peter Soelkner has been named managing director, and Oskar Gold will serve as vice president of the new entity. Headquarters will be in Ravensburg, Germany, and Vetter Pharma International USA, Inc. will be located in Yardley, PA.
“The formation of VPI allows us to better position ourselves as a worldwide leader in pre-filled aseptic injection solutions,” Soelkner said. “By creating an entity that focuses exclusively on sales, marketing and customer service on a global level, Vetter will move significantly closer to the international market and can build even stronger relationships with our clients and prospects throughout the world.”
VPF, which previously has managed all of Vetter’s sales, services and manufacturing activities under a single corporate umbrella, will now focus exclusively on the company’s manufacturing and pharmaceutical operations. “By realigning our resources to empower each entity’s core competencies, both VPI and VPF alike can be major catalysts in Vetter’s continued growth and expansion in the years to come—no matter how much the industry may change,” he added.
Peter Soelkner has been named managing director, and Oskar Gold will serve as vice president of the new entity. Headquarters will be in Ravensburg, Germany, and Vetter Pharma International USA, Inc. will be located in Yardley, PA.
“The formation of VPI allows us to better position ourselves as a worldwide leader in pre-filled aseptic injection solutions,” Soelkner said. “By creating an entity that focuses exclusively on sales, marketing and customer service on a global level, Vetter will move significantly closer to the international market and can build even stronger relationships with our clients and prospects throughout the world.”
VPF, which previously has managed all of Vetter’s sales, services and manufacturing activities under a single corporate umbrella, will now focus exclusively on the company’s manufacturing and pharmaceutical operations. “By realigning our resources to empower each entity’s core competencies, both VPI and VPF alike can be major catalysts in Vetter’s continued growth and expansion in the years to come—no matter how much the industry may change,” he added.
